Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biohaven Ltd.

NYSE: BHVN · Life Sciences · 5 alerts · CIK 1935979

Share price
$13.80Close, Nov 16
Market cap
$2.08B
Shares outstanding
151.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biohaven Ltd. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Investor Presentation

Biohaven Investor Presentation

Biohaven Ltd. is delivering an investor presentation at the Jefferies Global Healthcare Conference in London from November 16-19, 2026. The presentation provides a corporate update on the company's clinical pipeline, including programs in glutamate modulation, immunology, and oncology.

4:05 PM ET 8-K
Financial Results

Biohaven Financial Results

Biohaven Ltd. reported third quarter 2026 financial results and provided updates on its clinical pipeline, including the FDA's acceptance of the NDA resubmission for troriluzole. The company highlighted significant regional licensing deals with SK Biopharmaceuticals and Ono Pharmaceutical, which are expected to provide substantial near-term cash consideration.

“This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value. We are excited to have entered into the first ever regional collaboration for an extracellular protein degrader with Ono Pharmaceutical to develop and commercialize our MoDE IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan and the ASEAN region.”

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven

“Establishing these unique collaborations with two leading global drug development and commercialization companies is a testament to the impressive potential and versatility of our portfolio.”

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
4:05 PM ET 10-Q
Financial Results

Biohaven Q3 2026 Results: Net Loss of $129M, Loss Narrows

Biohaven Ltd. reported a net loss of $129.3 million for the third quarter of 2026, an improvement from the $173.4 million loss in the prior year period. The company continues to fund its clinical pipeline in immunology, obesity, and neuroscience, ending the period with $161.1 million in cash and marketable securities.

Key figure
Net loss $129M
7:00 AM ET 8-K
Business Update

Biohaven Business Update

Biohaven announced that the FDA has accepted its New Drug Application (NDA) resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia (SCA). The FDA has assigned a user fee goal date in the first quarter of 2027 and plans to convene an advisory committee meeting to review the application.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.